# A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction

> **NCT00554346** · PHASE4 · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 64 (estimated)

## Conditions studied

- Post-operational Pain

## Interventions

- **DRUG:** Arcoxia(etoricoxib 90 mg/tablet)

## Key facts

- **NCT ID:** NCT00554346
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2010-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00554346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00554346, "A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00554346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*